Literature DB >> 28919362

A homozygote TREX1 mutation in two siblings with different phenotypes: Chilblains and cerebral vasculitis.

Rabia Miray Kisla Ekinci1, Sibel Balci2, Atil Bisgin3, Derya Ufuk Altintas4, Mustafa Yilmaz5.   

Abstract

Three prime repair exonuclease 1 degrades single and double stranded DNA with 3'-5' nuclease activity and its mutations are related to type 1 IFN mediated autoinflammation due to accumulated intracellular nucleic acids. To date, several cases of systemic lupus erythematosus, Aicardi-Goutieres syndrome, familial chilblain lupus, retinal vasculopathy-cerebral leukodystrophy have been reported with TREX1 mutations. Chilblain lupus is a skin disease characterized by blue-reddish coloring, swelling or ulcers on acral regions of body such as fingertips, heels, nose and auricles. Central nervous system vasculitis is a prominent cause of childhood strokes. 10 families with familial chilblain lupus related to TREX1 mutations were reported previously in the literature, in which homozygote D18N variant in TREX1 gene was related to chilblains with cerebral vasculitis. In this report, whole-exome-sequencing revealed a homozygote R114C mutation in TREX1 gene was shown in two siblings with recurrent chilblains whom one of them was the second case accompanied by cerebral vasculitis in the literature. As a result, the approach of WES in clinical use revealed a novel mutation in clinically heterogenous patients to provide genetic counseling.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Autoinflammatory diseases; Cerebral vasculitis; Chilblain; TREX1

Mesh:

Substances:

Year:  2017        PMID: 28919362     DOI: 10.1016/j.ejmg.2017.09.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  8 in total

1.  Aicardi goutières syndrome is associated with pulmonary hypertension.

Authors:  Laura A Adang; David B Frank; Ahmed Gilani; Asako Takanohashi; Nicole Ulrick; Abigail Collins; Zachary Cross; Csaba Galambos; Guy Helman; Usama Kanaan; Stephanie Keller; Dawn Simon; Omar Sherbini; Brian D Hanna; Adeline L Vanderver
Journal:  Mol Genet Metab       Date:  2018-09-07       Impact factor: 4.797

2.  TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia.

Authors:  C Paradis; M Cadieux-Dion; C Meloche; M Gravel; J Paradis; A Des Roches; G Leclerc; P Cossette; P Begin
Journal:  J Clin Immunol       Date:  2019-01-26       Impact factor: 8.317

Review 3.  Insights Gained From the Study of Pediatric Systemic Lupus Erythematosus.

Authors:  Mindy S Lo
Journal:  Front Immunol       Date:  2018-06-05       Impact factor: 7.561

4.  Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib.

Authors:  Shiyu Zhang; Jiaxing Song; Yuyan Yang; Huilei Miao; Lu Yang; Yuehua Liu; Xue Zhang; Yaping Liu; Tao Wang
Journal:  Pediatr Rheumatol Online J       Date:  2021-01-06       Impact factor: 3.054

Review 5.  Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels.

Authors:  Thomas Renson; Lorraine Hamiwka; Susanne Benseler
Journal:  Front Pediatr       Date:  2022-08-10       Impact factor: 3.569

Review 6.  Lupus animal models and neuropsychiatric implications.

Authors:  Thaís Evelyn Karnopp; Gustavo Flores Chapacais; Eduarda Correa Freitas; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2020-11-06       Impact factor: 2.980

7.  Familial chilblain lupus due to a novel mutation in TREX1 associated with Aicardi-Goutie'res syndrome.

Authors:  Cuili Yi; Qiyuan Li; Jihong Xiao
Journal:  Pediatr Rheumatol Online J       Date:  2020-04-15       Impact factor: 3.054

8.  Different Clinical Manifestations of Three Prime Repair Exonuclease 1 Mutation: A Case Series.

Authors:  Faruk Incecik; Sibel Balci; Rabia Miray Kisla Ekinci; Ozlem M Herguner; Atil Bisgin; Mustafa Yilmaz
Journal:  Ann Indian Acad Neurol       Date:  2020-12-08       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.